Trial
NCT03035058
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Takeda
Collaborators
—
Condition
Primary Sclerosing Cholangitis
Intervention
Vedolizumab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-08